Mr. Aras Azadian reports

RETIREMENT OF CHANDRA PANCHAL, PHD FROM THE BOARD OF DIRECTORS

Dr. Chandra Panchal, PhD, is retiring as chairman of the board of directors of Avicanna Inc., and the company will initiate a search for a new director.

"We wish to express our deepest thanks to Dr. Panchal for all his time and all of his efforts during these past seven years that he has served as a member of the board of directors of the company. During his tenure with Avicanna, Dr. Panchal witnessed our evolution from a precommercial [research and development]-stage company into an international biopharmaceutical company, and assisted management with various external challenges and internal growing pains along the way," stated Aras Azadian, chief executive officer.

"It was an honour to have served as chairman of the board these past years. With the company recently closing a transformational acquisition, launching MyMedi.ca and reporting record revenues, I am proud of the company's management and employees who have developed Avicanna from a fledgling start-up to an international player in a short period of time. I believe now is the right time for me to retire from active board service at the company," stated Dr. Chandra Panchal, PhD.

About Avicanna Inc.

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform, including research and development and clinical development, that has led to the commercialization of more than 30 products across various market segments:

• Medical cannabis and wellness products (RHO Phyto): The formulary offers a diverse range of proprietary formulations, including oral, sublingual, topical and transdermal deliveries, with varying ratios of cannabinoids, and is supported with continuing patient and medical community education. RHO Phyto has been established as a leading medical brand in Canada, and is currently available nationwide to patients across several medical channels and continues to expand into new international markets.
• Pharmaceutical preparations and pipeline: Leveraging Avicanna's scientific platform, vertical integration and real-world evidence, Avicanna has developed an extensive pipeline of patent-pending drug candidates that are indication specific, and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain and various neurological disorders. Avicanna's first pharmaceutical preparation (Trunerox) is in the drug registration stage in South America.
• Medical cannabis care platform (MyMedi): MyMedi is Avicanna's medical cannabis care platform that is formed with the aim to better serve medical cannabis patients' needs and enhance the patient journey. MyMedi features diverse and scientifically curated products from leading Canadian licensed producers in addition to pharmacist-led patient support programs and educational resources to facilitate the incorporation of medical cannabis into health care regimens. MyMedi also provides specialty services to distinct patient groups such as veterans, and collaborating with public and private providers for adjudication and reimbursement.

We seek Safe Harbor.